A phase III clinical trial to investigate AST-VAC1 for the treatment of acute myelogenous leukaemia

Trial Profile

A phase III clinical trial to investigate AST-VAC1 for the treatment of acute myelogenous leukaemia

Planning
Phase of Trial: Phase III

Latest Information Update: 04 Nov 2016

At a glance

  • Drugs VAC 1 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Asterias Biotherapeutics
  • Most Recent Events

    • 04 Nov 2016 According to an Asterias Biotherapeutics media release, company will commenced this trial in 2018.
    • 24 Feb 2016 According to an Asterias Biotherapeutics media release, the results from this trial may support an accelerated development pathway and Biologics License Application (BLA) filing. Asterias plans to submit a request for a Special Protocol Assessment (SPA) to the FDA to confirm the primary endpoint and other design elements of this trial.
    • 12 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top